Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 GlobeNewswire November 06, 2025 The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Erasca, […]
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire November 06, 2025 WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy GlobeNewswire November 06, 2025 SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies
KBR, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – KBR GlobeNewswire November 06, 2025 LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) — The DJS Law Group reminds investors of a class action lawsuit against KBR, Inc. (“KBR” or “the Company”) (NYSE: KBR) for violations of §§10(b)
Nanox Collaborates with Leading Czech Medical Imaging Distributor EXRAY to Expand European Footprint GlobeNewswire November 06, 2025 EXRAY, leading Czech radiography supplier with 50%+ market penetration, to distribute Nanox's imaging solutions PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company,
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20 GlobeNewswire November 06, 2025 First large, randomized, placebo-controlled
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study GlobeNewswire November 06, 2025 HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab's ability to improve urticaria control
Terra Innovatum Global to Report Third Quarter 2025 Financial Results and Provide Business Update on November 17, 2025 GlobeNewswire November 06, 2025 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum” or the “Company“) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors, announced it will release its third quarter fiscal
Darktrace Recognized as the Only Customer's Choice Vendor in the 2025 Gartner(R) Peer Insights(TM) for Network Detection and Response Darktrace is the only vendor to be recognized as both a Leader in the 2025 Gartner(R) Magic Quadrant(TM) and a Customers' Choice for Network Detection and Response (NDR). Darktrace / NETWORK(TM) holds a 95% Willingness to
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI(TM) Launch Gains Momentum GlobeNewswire November 06, 2025 Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI received unique J-Code